Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/1346-8138.15292 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Initial Low-Dose Hydroxyurea and Anagrelide Combination in Essential Thrombocythemia: Comparable Response with Lower Toxicity.
J Clin Med
May 2024
Department of Hematology and Oncology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung 25440, Republic of Korea.
Essential thrombocythemia (ET) is a myeloproliferative neoplasm that overproduces platelets and is associated with life-threatening thrombosis. Medical cytoreduction either with hydroxyurea (HU) or anagrelide (AG) is widely used, but drug intolerance or resistance are major concerns. Low-dose combination of HU and AG as an alternative strategy has been explored in various studies.
View Article and Find Full Text PDFA Case Report of Ropeginterferon Alfa-2b for Polycythemia Vera during Pregnancy.
Hematol Rep
March 2023
Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Myeloproliferative neoplasms (MPN) such as essential thrombocythemia (ET) and polycythemia vera (PV) are rare during pregnancy. However, they are harmful because they are associated with an increased risk of thromboembolic, hemorrhagic, or microcirculatory disturbances or placental dysfunction leading to fetal growth restriction or loss. Low-dose aspirin and low-molecular-weight heparin (LMWH) are recommended to reduce pregnancy complications, and interferon (IFN) is the only treatment option for cytoreductive therapy based on the likelihood of live birth in pregnant women with MPN.
View Article and Find Full Text PDFA Young Adult With Essential Thrombocythemia Presenting as Myocardial Infarction.
Cureus
September 2022
Internal Medicine, Hackensack Meridian Health Ocean University Medical Center, Brick, USA.
Essential thrombocythemia (ET) is a myeloproliferative neoplasm involving the clonal proliferation of platelets. It is Philadelphia negative and is associated with Janus kinase 2 (JAK2), calreticulin (CALR), or myeloproliferative leukemia virus oncogene (MPL) mutations. The resultant platelets have quantitative and qualitative defects, making them more sticky and prone to thromboembolism.
View Article and Find Full Text PDFEssential Thrombocythemia in Children: A Retrospective Study.
J Hematol
June 2021
Department of Pediatric Hematology/Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Background: Essential thrombocythemia (ET) is one of the "classic" Philadelphia chromosome negative (Ph-) myeloproliferative neoplasms characterized by sustained thrombocytosis, increased megakaryopoiesis and high risk of vascular complications. ET is very rare in childhood. The annual incidence is approximately 1 per 10,000,000 in children less than 14 years, and about 60 times lower than adults.
View Article and Find Full Text PDFAdvances in the Treatment of Polycythemia Vera: Trends in Disease Management.
Cureus
March 2021
Internal Medicine, Government Medical College and Hospital, Chandigarh, Chandigarh, IND.
Article Synopsis
- Treatment options for polycythemia vera (PV) have changed; low-risk patients can often use phlebotomy and low-dose aspirin, while high-risk individuals require cytoreductive therapies.
- First-line treatments include hydroxyurea or interferons, with concerns about hydroxyurea's side effects and the benefits of newer interferon formulations.
- Second-line options like ruxolitinib and anagrelide, plus potential future treatments like givinostat and idasanutlin, are also part of the management strategy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!